Pankaj Agarwal

TaRCoS: Target ID and Drug Repurposing Consultative Solution, Bioinformatics; Physician & Scientist Recruiting

[Pankaj Agarwal @pa_agarwal]

Thanks to #ISMB2020/@ISCB: first talk ISMB'94 with @Rbaltman org.; org. ISMB '96 with @statesdj & @terrygaaster; lucky to help co-found @ISCB with @ProfLHunter et al. Left @GSK last year after 22 fabulous years. Excited to release my first product https://t.co/L87eiFrjUX.

[Pankaj Agarwal @pa_agarwal]

@ProfLHunter @ProfLHunter is a fabulous mentor as I have worked with some of his students.

[Pankaj Agarwal @pa_agarwal]

@RecursionChris @RecursionPharma Congrats Chris. Great way to pick a novel target. Kudos!!

[Pankaj Agarwal @pa_agarwal]

@d0choa Any metrics on the overall model to predict failure based on these properties? We should get a decent model given that properties don't appear to be correlated.

[Pankaj Agarwal @pa_agarwal]

@d0choa @d0choa nice study. Curious about the contribution of lack of GWAS to the failure outcome vs lack of Mendelian/Somatic?

[Pankaj Agarwal @pa_agarwal]

@nicktatonetti Congrats Nick. Your work has always been influential in the industry as well!

[Pankaj Agarwal @pa_agarwal]

Congratulations @kpfortney and the entire BioAge team. Tremendous validation of your AI-driven discovery platform and great news for patients.

[BioAge @bioagelabs]

BioAge is thrilled to share positive topline data from our Phase 1b trial of BGE-105 for muscle atrophy.

Our CEO @kpfortney on how these findings validate BioAge’s target discovery platform:

News release: https://t.co/yFMUZpeqwy

[BioAge @bioagelabs]

BioAge is thrilled to share positive topline data from our Phase 1b trial of BGE-105 for muscle atrophy.

Our CEO @kpfortney on how these findings validate BioAge’s target discovery platform:

News release: https://t.co/yFMUZpeqwy

[Pankaj Agarwal @pa_agarwal]

@drughuntersite @DennisWhom Wrong target: makes every other drug discovery concern immaterial.

[Pankaj Agarwal @pa_agarwal]

Very nice. @opentargets Which download files capture these new annotations? @Trozday and @lesya_rzvvsk is there a paper or preprint describing these results?

[Open Targets @OpenTargets]

Amongst the new features of this release, 2 are derived from Open Targets projects:

➡️ @TRozday’s #ML text-mining of drug indications DailyMed’s drug labels
➡️ @lesya_rzvvsk #NLProc classifications of why clinical trials stopped

[Pankaj Agarwal @pa_agarwal]

@josephmreplogle @xlw1207 @JswLab Joseph, great work. Are the transcriptomic signatures for each knockdown also available? Did not see those in the supplementary data.

[BioAge @bioagelabs]

WEBINAR: The story of BioAge’s apelin receptor agonist BGE-105, from initial target identification through preclinical validation and clinical development.

➡️ Register (free!): https://t.co/SJcOcnkOGJ

Wednesday, April 27, 1–2:15 PM EDT

[Pankaj Agarwal @pa_agarwal]

@FanZhang_Jessie it was a pleasure reading your application. Wish you great success.

[Dr. Fan Zhang ⛵️ @FanZhang_Jessie]

Excited🎉to share that we are selected to receive a Translational Medicine Research Grant from @PhRMAfoundation @PhRMA! We will develop #Singlecell #MachineLearning methods to decipher myeloid phenotypes on the lung-synovium axis in RA #rheumatology💊 Thank all my collaborators!!

[Nature Biotechnology @NatureBiotech]

We continue to celebrate outstanding leaders in biotech for #WomensHistoryMonth. Today we recognize Kristen Fortney, co-founder and CEO of BioAge, which is developing a pipeline of therapies that target aging in order to increase healthspan and address chronic diseases

[Pankaj Agarwal @pa_agarwal]

@sirotalab Great study. What was the effect in depressive disorder patients not on SSRIs?

[Sirota Lab at UCSF @SirotaLab]

New paper out!! 📰 In our multicenter study of 83,584 patients diagnosed with COVID-19, we found that SSRI use may reduce mortality among patients with COVID-19. Congrats to @tomiko22 @AliceTang_mstp @oskotsky @NimaAghaeepour @msirota84 and team! https://t.co/4dVeUlyXF7

[Pankaj Agarwal @pa_agarwal]

What are the implications of this on the massive effort in industry (& academia) on the variant to gene studies?

[Yang Luo @yluo86]

In contrary to the current variant-to-gene efforts, which assumes GWAS risk alleles must have some regulatory effects on gene expression (e.g. via eQTL, sQTL). Sunyaev Lab found limited evidence to support this assumption, and argues for alternative models.https://t.co/idDkKfmCHC

[Pankaj Agarwal @pa_agarwal]

@msirota84 @alitaubes @BenGlicksberg @tomiko22 @iditkosti @ParanjpeIshan @MesudeBicak @UCSF_BCHSI @UCSFPrecision @SirotaLab @msirota84: a repurposing for AD using cmap is really impressive. Would like to read the exciting details. Could you please share a PDF.

[Pankaj Agarwal @pa_agarwal]

@ProfLHunter Larry, how are you able to grow lychees in Colorado? Or have you moved to Hawaii?

[Pankaj Agarwal @pa_agarwal]

Wow! Congratulations.

[Kristen Fortney @kpfortney]

BioAge is bringing in a promising drug from Amgen! BGE-105 is an agonist of the APJ receptor, and we will take it into Ph1 in Q1’22. This is BioAge’s third clinical-stage drug candidate targeting an important mechanism of aging.

[Pankaj Agarwal @pa_agarwal]

@johnpoverington John, I had unsuccessfully looked for something similar. My best solution then was to look at EHRs to see repeat vs spot ICDs per patient.

[Pankaj Agarwal @pa_agarwal]

Great to see their S-1 IPO filing and the immense progress. Definitely recommend reading this for anyone interested in AI/ML in Drug Discovery. There is a fair bit of science in it. 7/7

https://t.co/1vKXsnK5XF

[Pankaj Agarwal @pa_agarwal]

I have long been a fan of drug discovery platforms that are biological agnostic. These provide a good counterbalance to the more common approach of identifying the "right" protein to target based on what we know about the disease and pathway today. 1/7

[Pankaj Agarwal @pa_agarwal]

I am fascinated by their 13B inferential relationships and hopefully, a significant fraction validates experimentally. These 13B relationships showcase the value of a broad agnostic platform. IMO, Recursion has one of the best data-driven drug discovery platforms today. 6/7